Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Proximod, a Selective Sphingosine-1-phosphate Receptor 1 Modulator in Patients With Moderate-to-severe Active Rheumatoid Arthritis: a Double-blind, Randomised, Placebo-controlled, Phase 2 Trial.

NCT07335952 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT07335952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07335952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Proximod, a Selective Sphingosine-1-phosphate Receptor 1 Modulator in Patients With Moderate-to-severe Active Rheumatoid Arthritis: a Double-blind, Randomised, Placebo-controlled, Phase 2 Trial.
Lead sponsor
Peking University People's Hospital
Phase
Phase 2
Overall status
Completed
Start date
September 2, 2024
Completion date
October 9, 2025
Enrollment
179 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis